Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A sensitive orange fluorescent calcium ion indicator for imaging neural activity.

Nature communications·2026
Same author

Intramedullary screw fixation of ballistic metacarpal and phalanx fractures.

JPRAS open·2026
Same author

Exploring technology-delivered cognitive training in the perioperative period for the prevention of postoperative delirium: a scoping review.

Psychology, health & medicine·2026
Same author

Avoiding Prostate Biopsy in Early Prostate Cancer Detection: From Liquid Biopsy to PSMA-PET.

European urology focus·2026
Same author

Reduced SH3RF3 May Protect Against Alzheimer's Disease by Lowering Microglial Pro-Inflammatory Responses via Modulation of JNK and NFkB Signaling.

Glia·2026
Same author

First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer.

Pierre-Yves Cren1, James Buteau2,3, Umma Fatema4

  • 1Department of Medical Oncology, Centre Oscar Lambret, Lille, France.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 7, 2026
PubMed
Summary
This summary is machine-generated.

A new framework guides metastatic castration-resistant prostate cancer (mCRPC) management by integrating clinical, molecular, and imaging data. This approach optimizes treatment sequencing and supportive care for improved patient outcomes.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Experiment Videos

Last Updated: May 9, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Area of Science:

  • Oncology
  • Medical Therapeutics
  • Patient Management

Background:

  • The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) has expanded significantly.
  • Earlier treatment intensification leads to complex clinical presentations at castration resistance onset.
  • Current treatment sequencing and decision-making require a more integrated approach.

Purpose of the Study:

  • To propose a pragmatic, patient-centered framework for managing mCRPC.
  • To integrate clinical features, molecular profiling, imaging, and supportive care into treatment decisions.
  • To guide clinicians in optimizing therapeutic strategies for mCRPC patients.

Main Methods:

  • Confirmation of castration resistance via biochemical or radiographic progression at castrate testosterone levels.
  • Treatment selection based on prior therapies, disease burden, symptoms, comorbidities, and frailty.
  • Molecular characterization for homologous recombination repair (HRR) alterations and mismatch repair deficiency (dMMR).
  • Utilizing Prostate-Specific Membrane Antigen (PSMA)-targeted radioligand therapy with PSMA-positron emission tomography (PET) based selection.
  • Incorporating early palliative care (EPC) and bone-protecting agents.

Main Results:

  • Molecular profiling identifies candidates for PARP inhibitors and immune checkpoint blockade.
  • PSMA-PET imaging aids in selecting patients for PSMA-targeted radioligand therapy.
  • Clinical factors like liver metastases and prior treatment response influence outcomes.
  • Early assessment of treatment response (PSA, PSMA-PET) supports adaptive strategies.
  • Bone-protecting agents reduce skeletal-related events; EPC improves quality of life.

Conclusions:

  • A comprehensive framework integrating diverse data improves mCRPC management.
  • Personalized treatment selection based on molecular and imaging biomarkers is crucial.
  • Early integration of supportive care, including EPC and bone protection, enhances patient well-being.
  • Adaptive treatment strategies informed by early response assessment are key to overcoming resistance.